Recently, the "2023 Yicai • China Corporate Social Responsibility List Awards Ceremony", hosted by Yicai, successfully concluded. For its high level of attention and continuous contribution to social needs, Sino Biopharm was honored with the "Social Innovation Contribution Award" on the "Yicai • China Corporate Social Responsibility List".

The "China Corporate Social Responsibility List", first held in 2008, has since formed a broad influence in society. This year's selection, with the annual theme of "Benevolent Business • Resilience and Symbiosis", lasted nearly half a year. Through layers of screening including questionnaire surveys, corporate interviews, expert reviews, and news observation, it aimed to discover outstanding models that align with the long-term development of business and society.

As a leading innovation and R&D-driven pharmaceutical group, Sino Biopharm adheres to internationalized innovation as a driver and continuously makes positive contributions to the improvement of human health and well-being. The Group is committed to providing patients with more accessible and affordable high-quality medication options, benefiting public welfare through practical actions. As of the end of 2022, the Group's key products have cumulatively treated over 150 million patients. At the same time, the Group persists in rare disease research to protect the health rights and interests of patients with rare disease. Currently, the Group has a total of 3 rare disease drugs on the market, and 5 rare disease drug projects under review or in development.

In the field of public welfare, Sino Biopharm focuses on charitable activities, rural revitalization, and inclusive healthcare, and continuously carries out public welfare activities. For example, since 2020, the Group's member company Chia Tai Tianqing has jointly launched the "Clear Sky Program" public welfare project with multiple parties to raise funds for families of patients with serious illnesses who are in need, to support their subsequent treatment. As of October 2022, the "Clear Sky Program" has raised a total of RMB 26 million, with more than 1.47 million participations in fundraising. The project also jointly launched an educational public welfare project for patients with advanced cancer with the Chinese Red Cross Foundation and others, aiming to enhance patients' understanding of tumor diagnosis, treatment, and rehabilitation through the promotion of science popularization education.

This award is an affirmation of Sino Biopharm and also motivates us to continue making progress. Facing various challenges such as global disease treatment difficulties, the Group will continuously innovate and break through, practice corporate leadership, and work with all sectors to jointly promote change.